XANTHINE OXIDASE INHIBITORY PROPERTIES OF 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES

Mihajlo Gajić1, Budimir S. Ilić2, Bojan P. Bondžić3, Zdravko Džambaski3, Ana Filipović3, Gordana Kocić4, Andrija Šmelcerović2

Xanthine oxidase (XO) is a versatile metalloflavoprotein enzyme that is best known for its rate-limiting role in the purine degradation pathway. Therapeutic inhibition of XO is based on its role in a variety of diseases that is attributed either to the hyperproduction of uric acid, or the hyperproduction of reactive oxygen species. Herein, we report the assessment of XO inhibitory properties of 24 1,2,3,4-tetrahydroisoquinoline derivatives, among which compound 16 exhibited IC50 value of 135.72 ± 2.71 µM. The interaction of compound 16 with XO enzyme was simulated using the Site Finder module, molecular docking and molecular dynamics. Molecular modeling suggests that interactions with Met 1038, Gln 1040, Thr 1077, Gln 1194 and Val 1259 are an important factor for inhibitor affinity toward the XO enzyme. Our proposed binding model might be beneficial for the discovery of new active 1,2,3,4-tetrahydroisoquinoline-based inhibitors of XO enzyme.

Acta Medica Medianae 2021;60(1):48-55.

Key words: xanthine oxidase inhibition, 1,2,3,4-tetrahydroisoquinolines, molecular docking, molecular dynamic simulation

Introduction

Xanthine oxidoreductase (XOR) is a versatile molybdoenzyme that exists in two interconvertible forms, xanthine oxidase (XO) and xanthine dehydrogenase (XDH) (1). The enzyme is best known for its rate-limiting role in the purine degradation pathway, where it catalyzes oxidative hydroxylation of hypoxanthine and xanthine, subsequently producing uric acid (2, 3). Dehydrogenase form is predominant in healthy tissues, while conversion to XO occurs in pathological conditions, after XDH proteolysis or oxidation of some of its sulfhydryl residues (1). Superoxide anion radical and hydrogen peroxide that are generated as the byproducts of enzyme activity are responsible for oxidative stress which usually accompanies elevated XO activity. The role of XO in diseases is attributed either to the hyperproduction of uric acid, or the hyperproduction of reactive oxygen species. Therefore, pharmacological inhibition of xanthine oxidase is proven to be invaluable for the treatment of hyperuricemia and gout in the first place, but might also be beneficial for plethora of conditions, such as cholecystitis, hemorrhagic shock, ischemia-reperfusion injuries, hypercholesterolemia and carcinogenesis (4).

Given the broad therapeutic potential of XO inhibitors, the aim of the current study was to assess a group of 24 1,2,3,4-tetrahydroisoquinoline derivatives for potential inhibitory properties against XO and to perform molecular docking and molecular dynamics simulation on active compounds, in order to elucidate key structural features responsible for XO inhibitory activity.

Materials and methods

Compounds

The synthesis of 24 1,2,3,4-tetrahydroisoquinoline derivatives was performed according to the description in our previous study (5).
Compounds were studied for inhibitory properties against bovine milk xanthine oxidase. Spectrophotometric measurement of uric acid formation at 293 nm was used for in vitro evaluation of enzyme inhibition, as described in our previous studies (6, 7). Initially, all compounds were assayed at a concentration of 150 μM, while those inhibiting more than 50% of enzyme activity were subsequently tested in a broader concentration range to allow for IC₅₀ determination. Allopurinol was used as a positive control. All experiments were performed in triplicate and averaged.

### Ligand preparation

Examined inhibitor was generated using the builder panel in the Molecular Operating Environment (MOE) 2019.0101 software (8). Using the MOE LigX module, partial atomic charges were ascribed and possible ionization states were generated at a pH of 7.0. The MMFF94x force field was used for optimization and the resulting structure was used for modeling studies. Conformational search was carried out by MOE LowModelMD method which performs molecular dynamic perturbations along with low frequency vibrational modes with energy window of 7 kcal/mol, and conformational limits of 1000.

### Receptor preparation

The X-ray crystallographic structure of XO enzyme (PDB code: 1N5X), retrieved from the Protein Data Bank, was prepared using the Structure Preparation process in MOE. After the correction, hydrogens were added and partial charges (Gasteiger methodology) were calculated. Energy minimization (AMBER14:EHT, RMS gradient: 0.100) was performed.

### Binding site selection

The Site Finder module of the MOE was used to identify possible ligand-binding sites within the optimized structure of XO enzyme. Hydrophobic or hydrophilic alpha spheres served as probes denoting zones of tight atom packing. These alpha spheres were utilized to define and rank potential ligand-binding sites according to their propensity for ligand binding (PLB) score, which was based on the amino acid composition of the pocket (9).

### Docking protocol

The molecular docking study was performed using the MOE to understand the ligand/protein interactions in detail. The default Triangle Matcher placement method was used for the induced fit docking. GBVI/WSA dG scoring function which estimates the free energy of binding of the ligand from a given pose was used to rank the final poses. The ligand/protein complex with lowest relative binding free energy (ΔG) score was selected for further study.

### Molecular dynamics simulation

The molecular dynamics simulation of compound 16 on XO enzyme, was carried out using the Desmond Molecular Dynamics System (Desmond) 2018.4 software (10). The structure of the added water was based on the simple point charge (SPC) solvent model. The system was neutralized with Na⁺ ions to balance the net charge of the whole simulation box to neutral. The final system contained approximately 123,000 atoms. The system was passed through a 6-step relaxation protocol before molecular dynamics simulations. The relaxed system was simulated for 10 ns, using a normal pressure temperature (NPT) ensemble with a Nosé–Hoover thermostat at 300 K and Martyna–Tobias–Klein barostat at 1.01325 bar pressure. Atomic coordinate data and system energies were recorded every 1 ps. The root mean square deviation (RMSD) and root mean square fluctuation (RMSF) of the inhibitor/XO enzyme complex were analyzed with respect to the simulation time.

### Results and discussion

Previously synthesized 1,2,3,4-tetrahydroisoquinoline derivatives (5) were assayed for potential in vitro XO inhibitory properties. Among 24 tested compounds (Table 1), IC₅₀ value below 150 μM was observed only in the case of 16 (135.72 ± 2.71 μM). Analysis of structural features of active compound 16 and its closest inactive analog 17 indicate to 7,8-dimethoxy substitution on 1,2,3,4-tetrahydroisoquinoline core as a probable cause for the lack of XO inhibitory properties of 17. Identified active compound 2-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-1-carbonitrile (16) was subjected to docking studies and molecular dynamics simulation with the goal to provide insight into the key structural features required for its XO inhibitory activity.

By combining a novel and highly effective algorithm for rapid binding-site evaluation with easy-to-use property visualization tools, Site Finder provides researchers with efficient means to identify and characterize binding sites (9). The results from the Site Finder analysis highlighted that catalytic residues like Gln 767, Glu 802, Arg 880, Phe 914, Phe 1009 and Glu 1261 (11, 12) constituted the top-ranked binding pocket of XO enzyme (Table 2, Figure 1).

The intermolecular contacts between examined inhibitor and XO enzyme were analyzed using the ligand interaction diagram of MOE suite (Table 3, Figure 2). It illustrates the existence of hydrogen bond and pi-H interactions. Additionally, the bond distances, bond energy and binding free energy between the inhibitor and receptor atoms were also examined (Table 3). The molecular docking highlighted the importance of Met 1038, Gln 1040, Thr 1077, Gln 1194 and Val 1259 in the formation of inhibitor/XO enzyme complex (Table 3, Figure 2). Observed interactions between 16 and non-catalytic...
residues (Table 3, Figure 2), are similar to molecular interplay involving non-purine XO inhibitors (13-16). Some of recently synthesized pyrazole derivatives were found to inhibit XO enzyme via Met 1038, Gln 1040 and Gln 1194 residues (13). Furthermore, inhibitory effect of verbascoside on XO activity, can be attributed to the formation of hydrogen bond with Gln 1194 residue (14). Moreover, molecular simulation revealed that newly synthesized hesperidin derivatives interacted with XO residues Met 1038, Gln 1040, Thr 1077, Gln 1194 and Val 1259 (15). Additionally, molecular docking revealed that 1,4-dicaffeoylquinic acid interacted with XO enzyme via Gln 1040 and Thr 1077 residues (16).

### Table 1. In vitro XO inhibitory activity of 1,2,3,4-tetrahydroisoquinolines

| Compd. | R1     | R2       | R3       | R4       | IC50 values (µM) ± SD |
|--------|--------|----------|----------|----------|-----------------------|
| 1      | H      | CH2COCH3 | H        | H        | > 150                 |
| 2      | H      | CH2COCH3 | OCH3     | OCH3     | > 150                 |
| 3      | Ph     | CH2COCH3 | H        | H        | > 150                 |
| 4      | Ph     | CH2COCH3 | OCH3     | OCH3     | > 150                 |
| 5      | Ph     | CH2COCH2CH3 | H        | H        | > 150                 |
| 6      | Ph     | CH2COCH2CH3 | OCH3     | OCH3     | > 150                 |
| 7      | Ph     | CH2COPh  | H        | H        | > 150                 |
| 8      | Ph     | CH2COPh  | OCH3     | OCH3     | > 150                 |
| 9      | Ph     | 2-oxocyclohexane | H        | H        | > 150                 |
| 10     | o-Me-Ph| CH2COCH3 | H        | H        | > 150                 |
| 11     | p-F-Ph | CH2COCH3 | H        | H        | > 150                 |
| 12     | p-F-Ph | CH2COCH3 | OCH3     | OCH3     | > 150                 |
| 13     | p-F-Ph | CH2COCH2CH3 | H        | H        | > 150                 |
| 14     | p-F-Ph | CH2COCH2CH3 | OCH3     | OCH3     | > 150                 |
| 15     | p-F-Ph | CH2COPh  | H        | H        | > 150                 |
| 16     | p-F-Ph | CN       | H        | H        | 135.72 ± 2.71         |
| 17     | p-F-Ph | CN       | OCH3     | OCH3     | > 150                 |
| 18     | p-F-Ph | 2-oxocyclohexane | H        | H        | > 150                 |
| 19     | p-F-Ph | 2-oxocyclohexane | OCH3     | OCH3     | > 150                 |
| 20     | p-Me-Ph| CH2COCH3 | H        | H        | > 150                 |
| 21     | p-Me-Ph| CH2COPh  | H        | H        | > 150                 |
| 22     | p-Me-Ph| CH2COPh  | OCH3     | OCH3     | > 150                 |
| 23     | p-Me-Ph| CH2COCH2CH3 | OCH3     | OCH3     | > 150                 |
| 24     | p-Me-Ph| CN       | OCH3     | OCH3     | > 150                 |
| Site | Size | PLB | Hyd | Side | Residues |
|------|------|-----|-----|------|----------|
| 1    | 172  | 1.31| 49  | 95   | Gln 112, Cys 150, Glu 767, Gly 796, Gly 797, Phe 798, Gly 799, Glu 802, Leu 873, Ser 876, Arg 880, Ala 910, Phe 911, Arg 912, Gly 913, Phe 914, Phe 1005, Ser 1008, Phe 1009, Thr 1010, Val 1011, Leu 1014, Met 1038, Gly 1039, Glu 1040, Gly 1041, Leu 1042, Lys 1045, Pro 1076, Thr 1077, Ala 1078, Ala 1079, Ser 1080, Val 1081, Ser 1082, Thr 1083, Ile 1190, Asp 1191, Gln 1194, Gly 1197, Lys 1257, Ala 1258, Val 1259, Gly 1260, Glu 1261 |
| 2    | 98   | 0.87| 35  | 63   | Cys 662, Val 663, Ile 696, Thr 697, Ile 698, Glu 699, Tyr 735, Gly 738, Glu 739, Asp 740, His 741, Asp 832, Met 833, Leu 834, Ile 835, Thr 836, Gly 837, Arg 839, Pro 841, Asn 866, Asn 904, Leu 905, Ser 906, Asn 908, Leu 1211, Tyr 1213, Ser 1214, Pro 1215, Gly 1217, Ser 1218, Leu 1219, Thr 1221, Arg 1222 |
| 3    | 101  | 0.68| 20  | 60   | His 614, Asp 651, Glu 652, Thr 653, Thr 661, Cys 662, Val 663, Gly 664, His 665, Ile 666, Pro 693, Ala 694, Ile 695, Ser 706, Tyr 707, Arg 802, Leu 804, Leu 834, Ile 835, Thr 836, Gly 837, Glu 868, Asn 869, Ser 870, Arg 871, Lys 902, Thr 903, Asn 904, Ser 906, Ser 907 |
| 4    | 185  | 0.59| 51  | 95   | Gin 62, Ile 66, His 67, Phe 68, Ser 69, Ser 123, Thr 126, Leu 127, Asn 130, Gin 131, Glu 137, Glu 138, Asp 141, Ala 142, Gin 144, Ala 304, Ser 306, Ser 307, Glu 309, Lys 310, Leu 313, Arg 328, Leu 331, Glu 332, Leu 334, Arg 335, Trp 336, Lys 340, Gin 341, Lys 343, Ser 344, Leu 548, Gin 550, Lys 551 |
| 5    | 95   | 0.54| 34  | 63   | Leu 952, Asn 956, Gin 957, Arg 958, Leu 959, Gin 960, Gly 961, Ser 963, Pro 1136, Asn 1137, Leu 1138, Asn 1148, Phe 1150, His 1151, Tyr 1152, Phe 1153, Tyr 1155, Asp 1181, Gly 1183, Cys 1247, Pro 1248, Asn 1249, Lys 1250, Lys 1251, Lys 1257 |

**Figure 1.** The top ranked XO binding site, represented by a grey-red surface map.
### Table 3. Summary of the 16 interactions with protein residues in XO

| Inhibitor | Inhibitor atoms | Protein residue | Inhibitor-Protein Interactions | Distance (Å) | E (kcal/mol) | ΔG binding (kcal/mol) |
|-----------|-----------------|-----------------|-------------------------------|--------------|-------------|----------------------|
| 16        |                 |                 |                               |              |             |                      |
| C10       | Met 1038        | H-donor         |                               | 4.29         | -0.3        |                      |
| C12       | Gln 1194        | H-donor         |                               | 3.06         | -0.5        |                      |
| N19       | Thr 1077        | H-acceptor      |                               | 3.47         | 2.2         |                      |
| 6-ring    | Gln 1040        | pi-H            |                               | 4.41         | -0.2        |                      |
| 6-ring    | Val 1259        | pi-H            |                               | 4.64         | -0.4        | -8.36                |

Figure 2. 3D/2D view of compound 16 (A, B) bound in the active site of XO. The polar part of the active site is shown as a pink surface, hydrophobic part as a green surface, while the solvent exposed part is shown as a red surface.

The study was further extended to assess the stability of 16/XO enzyme complex through the molecular dynamics simulation. The RMSD and RMSF plots for XO enzyme and examined inhibitor showed that docking complex was stable during entire simulation period (Figures 3-4). The RMSD for Ca, side chains and heavy atoms remained within the limit of 2 Å. The similar situation was noted for RMSF values. The obtained results indicated small structural rearrangements, less conformational changes and confirmed stability of 16/XO enzyme complex (17).

Figure 3. RMSD (A) and RMSF (B) plot of XO, obtained during the course of 10 ns molecular dynamics simulation.
Conclusion

A series of 24 1,2,3,4-tetrahydroisoquinoline derivatives were screened for potential XO inhibitory properties. Among them, only compound 16 (IC$_{50}$ = 135.72 ± 2.71 µM) exhibited IC$_{50}$ value below 150 µM, and was further subjected to molecular docking and molecular dynamic simulation. Molecular modeling suggests that interactions with Met 1038, Gin 1040, Thr 1077, Gin 1194 and Val 1259 are an important factor for inhibitor affinity toward the XO enzyme. Observed interactions with non-catalytic residues, might be beneficial for the discovery of new active 1,2,3,4-tetrahydroisoquinoline-based inhibitors of XO enzyme.

Acknowledgements

The financial support of this work by the Ministry of Education, Science and Technological Development of the Republic of Serbia (Grant numbers 451-03-68/2020-14/200113 and 451-03-68/2020-14/200026) and the Faculty of Medicine of the University of Niš (Internal project No. 40) are gratefully acknowledged. The authors would like to thank D. E. Shaw Research, for providing us the Desmond software package free of cost for this study.
Xanthine oxidase inhibitory properties of 1,2,3,4-tetrahydroisoquinoline...

References

1. Pacher PA, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006;58(1):87-114. [CrossRef][PubMed]
2. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 2004;555(3):589-606. [CrossRef][PubMed]
3. Ojha R, Singh J, Ojha A, Singh H, Sharma S, Nepali K. An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). Expert Opin Ther Pat 2017;27(3):311-45. [CrossRef][PubMed]
4. Šmelcerović A, Tomović K, Šmelcerović Ž, Petronijević Ž, Kocić G, Tomasić T, et al. Xanthine oxidase inhibitors beyond allopurinol and febuxostat: an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity. Eur J Med Chem 2017;135:491-516. [CrossRef][PubMed]
5. Džambaski Z, Bondžić BP. Dehydrogenative C(sp3)–H bond functionalization of tetrahydroisoquinolines mediated by organic oxidants under mild conditions. Org Biomol Chem 2019;17(26):6420-5. [CrossRef][PubMed]
6. Šmelcerović Ž, Veljković A, Kocić G, Yancheva D, Petronijević Ž, Anderluh M, Šmelcerović A. Xanthine oxidase inhibitory properties and anti-inflammatory activity of 2-amino-5-alkyldene-thiazol-4-ones. Chem Biol Interact 2015;229:73-81. [CrossRef][PubMed]
7. Tomović K, Ilić BS, Šmelcerović Ž, Miljković M, Yancheva D, Kocić G, Šmelcerović A. Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors. Chem Biol Interact 2020;315:108873. [CrossRef][PubMed]
8. MOE, Molecular Operating Environment (computer program). Version 2019.0101. Montreal (Canada): Chemical Computing Group ULC; 2019.
9. Soga S, Shirai H, Kobori M, Hirayama N. Use of amino acid composition to predict ligand-binding sites. J Chem Inf Model 2007;47(2):400-6. [CrossRef][PubMed]
10. Desmond, Desmond Molecular Dynamics System (computer program). Version 2018.4. New York (NY): D.E. Shaw Research; 2018.
11. Okamoto K, Matsumoto K, Hille R, Eger BT, Pai EF, Nishino T. The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci U S A 2004;101(21):7931-6. [CrossRef][PubMed]
12. Pauff JM, Cao H, Hille R. Substrate orientation and catalysis at the molybdenum site in xanthine oxidase crystal structures in complex with xanthine and lumazine. J Biol Chem 2009;284(13):8760-7. [CrossRef][PubMed]
13. Li P, Tian Y, Zhai H, Deng F, Xie M, Zhang X. Study on the activity of non-purine xanthine oxidase inhibitor by 3D-QSAR modeling and molecular docking. J Mol Struct 2013;1051:56-65. [CrossRef][PubMed]
14. Wan Y, Zou B, Zeng H, Zhang L, Chen M, Fu G. Inhibitory effect of verbascoside on xanthine oxidase activity. Int J Biol Macromol 2016;93:609-14. [CrossRef][PubMed]
15. Malik N, Dhiman P, Khatkar A. Mechanistic approach towards interaction of newly synthesized hesperidin derivatives against xanthine oxidase. Int J Biol Macromol 2019;135:864-76. [CrossRef][PubMed]
16. Cao W, Fang Y, Wu T, Liang F, Cheng Y, Salah M, et al. Insights from multispectral and molecular docking investigation on the xanthine oxidase inhibition by 1,4-dicaffeoylquinic acid. J Mol Struct 2020;128475. [CrossRef]
17. Liu K, Kokubo H. Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations: a cross-docking study. J Chem Inf Model 2017;57(10):2514-22. [CrossRef][PubMed]
INHIBICIJA KSANTIN OXIDAZE DERIVATIMA 1,2,3,4-TETRAHIDROIZOHINOLINA

Mihajlo Gajić¹, Budimir S. Ilić², Bojan P. Bondžić³, Zdravko Džambaski³, Ana Filipović³, Gordana Kocić⁴, Andrija Šmelcerović²

¹Univerzitet u Nišu, Medicinski fakultet, Katedra za farmaciju, Niš, Srbija
²Univerzitet u Nišu, Medicinski fakultet, Katedra za hemiju, Niš, Srbija
³Univerzitet u Beogradu, Institut za hemiju, tehnologiju i metalurgiju, Beograd, Srbija
⁴Univerzitet u Nišu, Medicinski fakultet, Katedra za biohemiju, Niš, Srbija

Kontakt: Andrija Šmelcerović
Bulevar dr Zorana Dindića 48, 18000 Niš, Srbija
E-mail: andrija.smelcerovic@medfak.ni.ac.rs
a.smelcerovic@yahoo.com

Ksantin oksidaza (XO) je metaloflavoproteinski enzim, koji je najpoznatiji po svojoj ulozi ograničavanja brzine razgradnje purinskih nukleotida. Terapijska inhibicija XO zasniva se na njenoj ulozi u brojnim bolestima, koje su povezane bilo sa hiperprodukcijom mokraćne kiseline ili hiperprodukcijom reaktivnih kiseoničnih vrsta. U ovom radu izvršeno je ispitivanje sposobnosti inhibicije XO 24 derivata 1,2,3,4-tetrahidroizohinolina, od kojih je jedinjenje 16 pokazalo IC₅₀ vrednost od 135,72 µM ± 2,71 µM. Interakcija jedinjenja 16 sa XO enzimom simulirana je korišćenjem Site Finder modula molekularnog dokinga i molekularne dinamike. Molekulsko modelovanje ukazuje na to da su interakcije sa Met 1038, Gln 1040, Thr 1077, Gln 1194 i Val 1259 važan faktor postojanja afiniteta inhibitora prema XO enzimu. Naš predloženi model vezivanja mogao bi biti od značaja za razvoj novih aktivnih inhibitora XO zasnovanih na 1,2,3,4-tetrahidroizohinolininskom heterociklusu.

Acta Medica Medianae 2021;60(1):48-55.

Ključne reči: inhibicija ksantin oksidaze, 1,2,3,4-tetrahidroizohinolin, molekularni doking, simulacija molekularne dinamike

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) Licence